10 Approvals To Watch For In Early 2017

The increasingly crowded immunology/inflammation market is set to receive some new entrants this year, with Sanofi /Regeneron Pharmaceuticals Inc.'s Dupixent (dupilumab), a potential first-in-class IL4-receptor antibody that inhibits signaling of IL-4 and IL-13, two key cytokines required for the type 2 (including Th2) immune response. The indication under review is atopic dermatitis, but Dupixent is being developed under five different allergic indications, with pivotal Phase III trials in asthma ongoing and filings due by year end. Regeneron believes it has found the “control point” for a variety of allergic diseases and that this drug can be expanded to indications including food allergies.